Cross-reactivity of the CEDIA buprenorphine assay in drugs-of-abuse screening: influence of dose and metabolites of opioids

Jon Andsnes Berg¹

Jan Schjøtt^{1,2}

Kjell O Fossan¹

Bettina Riedel^{1,2}

¹Section of Clinical Pharmacology,
Laboratory of Clinical Biochemistry,
Haukeland University Hospital,

²Faculty of Medicine and Dentistry,
Department of Clinical Science,
University of Bergen, Bergen, Norway

Purpose: The cloned enzyme donor immunoassay (CEDIA) for buprenorphine is applied for both urine drugs-of-abuse screening and compliance monitoring. Sensitivity, specificity, and optimal cutoff of this assay have differed between studies. This may indicate that cross-reactivity has to be taken into account during assay evaluation. We therefore investigated the performance of the CEDIA buprenorphine assay for use in our patient population and explored the impact of cross-reactivity on assay accuracy.

Methods: The CEDIA buprenorphine assay and high-performance liquid chromatography–tandem mass spectrometry were employed to analyze drugs-of-abuse in urine samples from a healthy drug-naïve male volunteer after intake of two tablets of a prescription drug containing 400 mg paracetamol +30 mg codeine phosphate, and in urine samples (n=2,272) from drug-addicted patients. Receiver operating characteristic analyses were performed to express the diagnostic accuracy of the CEDIA buprenorphine assay.

Results: CEDIA buprenorphine was positive in one urine sample from the drug-naïve person after intake of the prescription drug. Twenty-five (1.1%) of the patient urine samples were positive for buprenorphine by CEDIA, but negative by high-performance liquid chromatography–tandem mass spectrometry. Codeine, morphine, and their respective metabolites were prevalent in samples that were false positive for buprenorphine. The specificity of the CEDIA buprenorphine assay increased to 99.7% when the cutoff was increased from 5 ng/mL to 10 ng/mL.

Conclusion: Intake of a therapeutic dose of codeine can yield a false-positive CEDIA buprenorphine result. Additive effects from metabolites of codeine contribute to cross-reactivity in concentrations much lower than listed in the manufacturer's cross-reactivity guide. Raising the cutoff from 5 ng/mL to 10 ng/mL increased the diagnostic accuracy. Clinicians should be informed about the risk of false-positive results with the CEDIA buprenorphine assay.

Keywords: buprenorphine, codeine, cross-reactivity, urine drugs-of-abuse screening, immunoassay

Introduction

Buprenorphine is a partial agonist/antagonist on the opioid receptors and may be prescribed both as an analgetic and in medication-assisted rehabilitation (MAR) of opioid-dependent patients.¹ Buprenorphine was reported as the third most prevalent misused opioid, next to heroin and methadone.² Although it seems to be more frequently misused in Europe and Asia than in the US,³ a 384% increase of misuse has been reported between 2006 and 2011 in the US.⁴ Thus, urine drug screening of buprenorphine is used to monitor compliance in MAR and side abuse.⁵

Chromatographic methods with mass spectrometry have high diagnostic accuracy but are time consuming and resource demanding.⁶ Immunochemical methods may be

Correspondence: Jon Andsnes Berg
Section of Clinical Pharmacology,
Laboratory of Clinical Biochemistry,
Haukeland University Hospital,
Jonas Lies vei 65, 5021 Bergen, Norway
Tel +47 5597 7852
Email jon.andsnes.berg@helse-bergen.no

preferential because they do not require the same degree of training and competence among laboratory staff and because they have a fast response time.⁷

Cross-reactivity leading to false-positive results is a known problem when using immunochemical methods.⁸ The producer of the cloned enzyme donor immunoassays (CEDIAs) has published a cross-reactivity guide⁹ that presents an overview over compounds that gave false-positive results in samples spiked with the potential cross-reactant over a range of clinically achievable concentrations. However, cross-reactivity with metabolites was not fully evaluated. Furthermore, in a clinical setting, several structurally related substances may be present simultaneously in urine samples from addicted patients, which may increase the potential of unintended analytical interference. The CEDIA buprenorphine assay has been associated with cross-reactivity with various substances, especially structurally related opioids such as morphine and codeine.^{5,10,11} Both sensitivity and specificity have differed between studies of this assay, even though a cutoff of 5 ng/mL was applied in all.^{5,10,12} Typically in these cases, the signal in the false-positive samples has been only slightly above the manufacturer's recommended 5 ng/mL cutoff concentration. Hence, the choice of an appropriate cutoff is of particular relevance for the performance of the CEDIA buprenorphine assay in a given population.

The urine drugs-of-abuse screening panel in our laboratory is used in a therapeutic setting and covers commonly abused drugs such as amphetamines, benzodiazepines, and opioids, including methadone and buprenorphine, which are of particular relevance to patients included in MAR. Positive buprenorphine screening results, indicating buprenorphine abuse in patients not treated with buprenorphine, could trigger a tighter therapeutic control or imply more serious consequences, such as exclusion from institutional therapy or loss of social benefits. This underlines that analytical specificity is of greater therapeutic significance than sensitivity. We regularly receive inquiries from clinicians questioning positive CEDIA buprenorphine results.

We therefore examined cross-reactivity by comparing the results obtained by CEDIA with those acquired by high-performance liquid chromatography–tandem mass spectrometry (HPLC-MS/MS). We first examined whether intake of a therapeutically recommended dose of a codeine preparation could yield false-positive CEDIA buprenorphine results. We then investigated which cutoff concentration would render the best diagnostic accuracy in a population associated with drug abuse.

Methods

Sample materials

The study material included anonymous, retrospective data used for quality control purposes in our department. The case study included only one of the authors (JS), and involved no patients. Thus, the study did not need formal approval or registration as a clinical trial according to the guidelines of the Regional Committee for Medical and Health Research Ethics and the Norwegian Data Protection Officer for Research at the Haukeland University Hospital. Furthermore, no patient consent was necessary.

In the case study, one healthy drug-naïve male volunteer (JS) was given two tablets of Paralgin Forte® (codeine phosphate 30 mg/paracetamol 400 mg). Sixteen urine samples, including one sample collected before administration of the drug, were collected from the volunteer during the following 55 hours. The samples were analyzed for buprenorphine with the CEDIA assay and for opioids and metabolites, including codeine with HPLC-MS/MS.

In the performance study, 2,272 urine samples that had been sent to the laboratory at the Haukeland University Hospital for drugs-of-abuse screening during a 4-week period were analyzed with both CEDIA and HPLC-MS/MS. Samples were taken from patients treated with either buprenorphine or methadone in specialized MAR clinics and from patients in general practices, psychiatric wards, outpatient clinics, emergency units, and other treatment institutions for drug addiction. Based on the information given on the requisition forms, 43% (n=996) of the patients were MAR patients. Due to the possibility of cross-reactivity in the immunochemical methods, all samples were analyzed for the complete drugs-of-abuse panel available at our laboratory, regardless of which analyses that had been required.

Analytical methods

All urine samples were tested for specimen validity tests including creatinine and pH before parallel analysis of CEDIA and HPLC-MS/MS. Urine samples with creatinine concentrations >2.3 mg/dL and with pH between 4.5 and 8.0 were considered valid.

The CEDIA buprenorphine assay was performed on AU-680 (Beckman Coulter Biomedical Limited, Brea, CA, USA), and the reagents were supplied by Thermo-Fischer Scientific (Waltham, MA, USA). The assay was performed semiquantitatively using calibrators for buprenorphine containing 0 ng/mL, 5 ng/mL, 20 ng/mL, and 50 ng/mL. According to the manufacturer's recommendation, we employed a cutoff concentration of 5 ng/mL for buprenorphine. The total analytical imprecision was

<9% at the manufacturer's recommended cutoff concentration. Total analytical imprecision was calculated using one measurement per day for 30 days. Imprecision measurement for CEDIA buprenorphine was performed with CEDIA buprenorphine, low and high controls, and with drugs of abuse (DOA) total level 4. All control materials were supplied by Thermo-Fischer Scientific. The CEDIA buprenorphine assay is reported to have cross-reactivity of 100% for buprenorphine and for buprenorphine-3-glucuronide, but no cross-reactivity for norbuprenorphine or norbuprenorphine-3-glucuronide.⁹ Performance of the CEDIA buprenorphine assay was investigated by comparison with HPLC-MS/MS. The samples were prepared using a Hamilton AT2plus (Hamilton Robotics GmbH, Martinsried, Germany) and analyzed on an API 2000 (AB Sciex, Stockholm, Sweden) with a TurboIonSpray-ionization source and an 1100-series HPLC-system (Agilent Technologies, Waldbronn, Germany). Separation was achieved using a Supelco Ascentis Phenyl, 2.1 mm × 50 mm, 3 μm analytical column maintained at 30°C (Sigma-Aldrich, St Louis, MO, USA) using gradient elution with 0.1% formic acid in water and acetonitrile as mobile phases. The sample preparation consisted of a twofold dilution with eleven deuterated internal standards and 0.1% formic acid in water. No preanalytical hydrolysis was performed. Only one multiple reaction monitoring-transition per analyte was monitored. However, both the parent drug and at least one metabolite were monitored. This was done because some analytes showed limited fragmentation and the presence of metabolites confirms intake of a specific drug. The limit of detection for buprenorphine, buprenorphine-glucuronide, norbuprenorphine, and norbuprenorphine-glucuronide was 0.9 ng/mL, 1.8 ng/mL, 1.9 ng/mL, and 2.4 ng/mL, respectively. Total analytical imprecision at 10 ng/mL was 14.7%, 18.6%, 32.9%, and 29.8% for buprenorphine, buprenorphine-glucuronide, norbuprenorphine, and norbuprenorphine-glucuronide, respectively. The method also included analyzes of codeine and morphine and its metabolites, other opioids, and other drugs-of-abuse. Analytical performance data for these analytes as measured by HPLC-MS/MS is given in Table S1.

In order to increase specificity, total buprenorphine, norbuprenorphine, and benzodiazepines were additionally analyzed with a different HPLC-MS/MS method, which involved enzymatic hydrolysis. The sample preparation consisted of a twofold dilution with β-glucuronidase (5,000 units/mL urine) from *Escherichia coli* (G7396, Sigma-Aldrich), eight deuterated internal standards and BIS-TRIS–propane buffer (pH 6.8). The samples were then incubated at 37°C for 2 hours. The hydrolysis was stopped by ultrafiltration using

a 10 kD membrane filter plate (MultiScreen Ultracel-10; Merck Millipore, Billerica, MA, USA). Two multiple reaction monitoring-transitions per analyte were monitored with set criteria for relative intensity, which gives identification points considered to provide reliable analyte identification.¹³ The acceptance criteria for quantifier and qualifier ions were a signal-to-noise ratio of ≥ 10 and ≥ 3 , respectively. The efficiency of the hydrolysis step for buprenorphine-glucuronide was evaluated in each sample by comparing the results of the two HPLC-MS/MS methods.

Validation included linearity of the method, limits of detection and quantification, imprecision and accuracy, matrix effect, carryover, hydrolysis efficiency, chromatographic interferences, and stability of processed samples. Quality control of the HPLC-MS/MS methods was performed using home-made spiked urine control material. Duplicate quality controls with two concentration levels were included in every series. The methods are part of the Labquality's EQA (external quality assessment) program for drug abuse screening in urine and LGC Standards drugs of abuse in urine PT (proficiency testing) scheme.

Cross-reactivity of codeine-6-glucuronide (C6G) in the CEDIA buprenorphine assay was tested with spiked aliquots of the same negative urine sample pool from three healthy volunteers. The C6G analytical reference standard was supplied by Lipomed AG (Arlesheim, Switzerland). The aliquots were spiked with different amounts of C6G giving C6G concentrations of 10,000 ng/mL, 20,000 ng/mL, 30,000 ng/mL, and 40,000 ng/mL, before they were analyzed with the CEDIA buprenorphine assay.

Statistical analysis

In the patient samples, we defined true-positive results to be positive with both HPLC-MS/MS and CEDIA. True negative results were negative with both HPLC-MS/MS and CEDIA. False-positive samples were positive with CEDIA, but negative with HPLC-MS/MS, whereas false-negative samples were negative with CEDIA, but positive with HPLC-MS/MS. From these results, we calculated sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy using Bayesian analysis.¹⁴ To find the most favorable CEDIA cutoff for buprenorphine in terms of highest specificity and sensitivity, we performed a receiver operating characteristic (ROC) analysis using Analyse-it (Analyse-it Software, Ltd, Leeds, UK). SPSS 20.0 (IBM Corporation, Armonk, NY, USA) was otherwise used to analyze the data. Pearson product moment correlation was used to analyze the relationship between C6G and CEDIA buprenorphine.

Results

Case study

CEDIA buprenorphine assay yielded a positive result above the recommended cutoff concentration at 5 ng/mL in the first out of 15 urine samples collected 5 hours after a single administration of 60 mg of codeine phosphate and 800 mg of paracetamol (Table 1). The concentration of codeine, norcodeine, and C6G in that specific sample was 2,550 ng/mL, 490 ng/mL, and 38,467 ng/mL, respectively, as determined by HPLC-MS/MS. The creatinine concentration was 11.2 mg/dL. Response in the CEDIA buprenorphine assay was observed over 15 hours after administration, but it was below cutoff of 5 ng/mL in all other samples but the first. No other drugs-of-abuse were detected with HPLC-MS/MS. In all samples, creatinine concentrations were between 2.3 mg/dL and 18.6 mg/dL, and pH was between 5.6 and 6.7.

The relationship between C6G concentrations and the signal in the CEDIA buprenorphine assay was linear (correlation coefficient = 0.998) in negative urine samples spiked with C6G. A concentration of 40,000 ng/mL yielded a signal corresponding to 6.2 ng/mL in the CEDIA buprenorphine assay.

Performance study

Table 2 shows the distribution of the most frequently detected drugs in 2,272 patient urine samples. Almost half of the samples contained benzodiazepines, and clonazepam, and oxazepam were detected most frequently. Opioids other than

methadone and buprenorphine were detected less frequently. Almost 5.4% of the samples were positive for morphine and 2.5% for codeine. CEDIA rendered no false-negative results for buprenorphine, and the NPV was one in the 2,272 patient samples. Twenty-five urine samples (1.1%) had a positive buprenorphine result with the CEDIA assay in concentrations ranging from 5.00 ng/mL to 18.20 ng/mL, but no buprenorphine or metabolites detected by HPLC-MS/MS. Eighteen of these samples (72%) were positive for both codeine and morphine-3-glucuronide (M3G) in a concentration range of 1,018–13,561 ng/mL, and 784–178,586 ng/mL, respectively (Table 3). Sixteen of these samples were also positive for morphine (17–37,665 ng/mL), and eleven for methadone (519–52,592 ng/mL). Five other samples were positive for methadone (9,446–41,866 ng/mL), either in addition to other drugs, such as oxazepam, delta-9-tetrahydrocannabinol, and zopiclone (n=3), or alone (n=2). One sample contained only oxazepam at a very low concentration, and in one other sample, no drugs or their metabolites were detected with our HPLC-MS/MS method. Taken together, the prevalence of false-positive urine samples for buprenorphine with the CEDIA assay was 1.1%, the sensitivity was 100%, the specificity was 98.0%, and the PPV was 0.957. In these 25 samples, the lowest creatinine concentration was 3.9 mg/dL, the highest 50.4 mg/dL, and pH was between 5.4 and 7.6.

An increase in the cutoff concentration of the CEDIA buprenorphine assay would reduce the number of false-positive results but would render an increase in the number of

Table 1 Results from urine samples (n=15) after ingestion of two tablets of a prescription drug containing 400 mg paracetamol +30 mg codeine phosphate by a healthy drug-naïve male volunteer

Time ^a	CEDIA (ng/mL)	HPLC-MS/MS (ng/mL)					
	Buprenorphine	C6G	Codeine	Norcodeine	Morphine	M3G	M6G
05.00	6.9	38,467	2,550	490	150	6,090	1,510
07.00	2.4	11,079	390	110	30	1,500	290
09.00	2.9	17,308	490	180	30	2,320	480
10.00	1.3	5,183	150	60	0	620	130
14.00	1.4	7,275	290	100	50	2,220	460
15.00	0.5	4,665	240	70	50	2,850	490
22.25	0.2	3,371	130	60	50	2,070	330
27.00	0	775	30	0	30	1,060	250
30.00	0.1	0	0	0	0	610	120
34.25	0	0	0	0	20	860	160
39.00	0	0	0	0	0	800	160
46.25	0	0	0	0	10	550	110
50.34	0.1	0	0	0	0	300	0
51.55	0.2	0	0	0	0	0	0
55.00	0	0	0	0	0	0	0

Note: ^aTime is given in hours and minutes after drug ingestion.

Abbreviations: CEDIA, cloned enzyme donor immunoassay; HPLC-MS/MS, high-performance liquid chromatography–tandem mass spectrometry; C6G, codeine-6-glucuronide; M3G, morphine-3-glucuronide; M6G, morphine-6-glucuronide.

Table 2 Frequency and share of positive results for drugs-of-abuse in patient urine samples (n=2,272), as determined by screening with HPLC-MS/MS

Substance	Positive results	
	n	%
6-Monoacetylmorphine	34	1.5
Amphetamine	258	11.4
Benzodiazepines	959	42.2
Buprenorphine	711	31.3
Codeine	56	2.5
Methadone	664	29.2
Methamphetamine	320	14.1
Morphine	123	5.4

Abbreviation: HPLC-MS/MS, high-performance liquid chromatography–tandem mass spectrometry.

false-negative results instead. In a ROC curve for the buprenorphine assay, the area under the curve was approaching 1, which indicated a very good diagnostic accuracy. Figure 1 shows PPV and NPV for CEDIA buprenorphine cutoff concentrations, ranging from 0 ng/mL to 49 ng/mL. The ROC analysis indicated that a cutoff concentration of 11.2 ng/mL would give the best accuracy, with four false-positive and two false-negative results, giving a PPV of 0.994 and a NPV of

0.999. A cutoff concentration of 8.2 ng/mL would render no false-negative, but ten false-positive results.

Discussion

Principal findings

A single intake of a recommended therapeutic dose of 60 mg codeine phosphate generated a false-positive CEDIA buprenorphine result. The concentration of codeine in this sample was 2,550 ng/mL. Codeine, morphine, and their respective metabolites were present in most of the false-positive patient urine samples. Raising the cutoff of the CEDIA buprenorphine assay from 5 ng/mL to 11.2 ng/mL decreased the risk of false-positive results, with only a modest increase in false-negative results giving both acceptable sensitivity and specificity.

Strengths and limitations

Cross-reactivity in the CEDIA buprenorphine assay has been described previously through experiments with spiked samples and in clinical case reports of false-positive urine samples.^{5,9} In the present study, cross-reactivity was assessed in a drug-naïve person and in a large patient material

Table 3 Results from CEDIA and HPLC-MS/MS in 25 urine samples with false-positive CEDIA buprenorphine

CEDIA (ng/mL)	HPLC-MS/MS (ng/mL)					
Buprenorphine	C6G	Codeine	Norcodeine	Morphine	M3G	M6G
18.20	91,294	13,561	4,166	200	3,138	646
18.10	17,165	1,018	788	26	784	185
16.70	0	0	0	0	0	0
15.00	41,938	5,149	1,121	57	2,538	600
11.20	9,415	2,335	1,070	37,665	139,823	48,915
10.60	11,602	3,832	970	27,621	178,586	68,758
9.60	11,174	1,766	143	36,253	120,903	46,146
8.60	0	0	0	0	0	0
7.60	4,279	1,467	51	29,390	125,056	48,454
7.30	4,336	1,168	94	23,826	127,825	42,778
7.10	37,801	2,096	1,067	29	2,123	415
7.10	12,172	2,604	1,104	14,096	148,129	46,608
6.90	29,861	3,682	705	314	9,137	1,661
6.90	0	0	0	0	0	0
6.80	24,820	1,736	297	19,118	117,673	40,609
6.80	0	0	0	0	0	0
6.30	2,948	1,078	86	12,441	97,368	20,997
6.30	0	0	0	0	0	0
6.20	30,479	5,868	962	86	1,154	231
6.00	0	0	0	0	0	0
5.90	8,464	1,527	611	9,245	105,213	31,656
5.80	27,626	1,676	1,273	57	3,092	461
5.40	19,020	1,078	514	17	3,461	600
5.20	6,419	1,197	254	8,389	108,444	23,073
5.00	0	0	0	0	0	0

Abbreviations: CEDIA, cloned enzyme donor immunoassay; HPLC-MS/MS, high-performance liquid chromatography–tandem mass spectrometry; C6G, codeine-6-glucuronide; M3G, morphine-3-glucuronide; M6G, morphine-6-glucuronide.

Figure 1 PPV and NPV with different cutoff concentrations of CEDIA for buprenorphine in patient urine samples ($n=2,272$).

Abbreviations: PPV, positive predictive value; NPV, negative predictive value; CEDIA, cloned enzyme donor immunoassay.

associated with drug abuse. Importantly, our results demonstrate that false-positive results in the CEDIA buprenorphine assay can occur after intake of a low dose of codeine by a person not associated with drug abuse. By using a known drug-naïve person, we minimized the risk of other possible cross-reactants that could cause a false-positive buprenorphine assay. We cannot completely rule out that paracetamol or its metabolites could cross-react with the CEDIA buprenorphine assay. Paracetamol is found on the negative list in the CEDIA buprenorphine assays cross-reactivity guide, tested in a concentration of 500,000 ng/mL.⁹ Considering that the chemical structure is quite different from buprenorphine, significant cross-reactivity with paracetamol is unlikely.

The patient samples in our study are representative for the target population of our drugs-of-abuse screening panel. This is illustrated by the high prevalence of positive results for several drugs-of-abuse. Our study results may demonstrate the magnitude of false-positive buprenorphine samples in a typical population for the use of drugs-of-abuse assays and as such represent a complement to cross-reactivity data supplied by the manufacturer. The presented data are generated from samples collected in a naturalistic setting with limited access to structured detailed information, including drug abuse pattern, treatment modalities, or the presence of other diseases. Hence, differences in cross-reactivity between subgroups within this population could not be addressed. In particular, our study is limited by the fact that we do not have a complete drug subscription status of the patients. We therefore do not know whether substances other than the analyzed drugs-of-abuse could be present in urine samples, causing false-positive

CEDIA buprenorphine. For instance, in one case report, the antipsychotic amisulpride caused cross-reactivity with buprenorphine.¹⁵ In addition, our HPLC-MS/MS method only detects known analytes and has no screening option for other structurally related substances.

Possible cross-reactants

The manufacturer's cross-reactivity guide serves to evaluate unexpected positive result in the CEDIA buprenorphine assay. According to this guide, the lowest concentration of codeine that yielded a false-positive result for buprenorphine was 34,000 ng/mL. This is in accordance with the data from spiked samples in other studies.^{5,11} In our study, the codeine concentrations associated with false-positive CEDIA buprenorphine were considerably lower, in the range of 1,000–13,500 ng/mL. This indicates that codeine alone did not cause the false-positive results. In the 18 samples with codeine, we also detected either codeine metabolites or other opioids and their metabolites. In our case study, the sample with a false-positive buprenorphine result had a concentration of 490 ng/mL and 38,467 ng/mL of norcodeine and C6G, respectively, in addition to codeine at a concentration of 2,550 ng/mL. One of the patient samples in the performance study contained C6G in a concentration >50,000 ng/mL. Several samples contained C6G in concentrations between 20,000 ng/mL and 50,000 ng/mL, concentrations that may have contributed to a false-positive buprenorphine result. These data are in accordance with data from Böttcher and Beck who demonstrated that C6G in a concentration of 50,000 ng/mL gave a result around the CEDIA buprenorphine cutoff of 5 ng/mL.⁵ To confirm these findings, we spiked negative urine samples with C6G and found that a concentration of 40,000 ng/mL yielded a signal corresponding to 6.2 ng/mL in the CEDIA buprenorphine assay.

Norcodeine concentrations were low (<4,200 ng/mL) in urine samples, which were false positive for buprenorphine. The manufacturer's cross-reactivity guide did not evaluate norcodeine, but cross-reactivity with the CEDIA buprenorphine assay has been demonstrated when norcodeine concentrations were 100,000 ng/mL.⁵ Based on these data, the contribution of norcodeine to the overall cross-reactivity in our study population is probably negligible.

Some of the false-positive patient samples also contained morphine, M3G, morphine-6-glucuronide (M6G) in high enough concentrations to contribute to cross-reactivity. In a study where urine samples were spiked with different opioids, they showed cross-reactivity in the CEDIA buprenorphine assay for all the tested opioids.¹¹ In a sample spiked with a

combination of dihydrocodeine and several metabolites of dihydrocodeine, in concentrations lower than what should give significant cross-reactivity for each substance alone, CEDIA yielded a positive buprenorphine result, indicating additive interference. We therefore suggest that a sum of structurally related compounds yielded a response above cutoff in the CEDIA buprenorphine assay in most of the false-positive samples in our study, although the concentration of each of them separately was lower than what is shown to give cross-reactivity in spiked samples.

In seven of the samples with false-positive CEDIA buprenorphine, no codeine, morphine, or their metabolites were detected with our HPLC-MS/MS method. Methadone was detected in five of these samples, oxazepam in two, and delta-9-tetrahydrocannabinol and zopiclone in one. Methadone was the only detected substance in two of the five false-positive samples. Methadone concentrations $>320,000$ ng/mL have been shown to give significant cross-reactivity in the CEDIA buprenorphine assay.¹¹ The methadone concentrations in these two samples and the other methadone-positive samples in our study material were considerably lower (all $<53,000$ ng/mL). Oxazepam, delta-9-tetrahydrocannabinol, and zopiclone are structurally unrelated to opioids and are not known to cross-react with the CEDIA buprenorphine assay according to the manufacturer's guide.⁹ Although we cannot rule out that these drugs could have contributed to a false-positive buprenorphine result, these seven samples may have contained known cross-reactants that we did not analyze for, such as amisulpride and quetiapine.⁹

Urine codeine concentration

Codeine is reported to have interindividual pharmacokinetic variability,¹⁶ and it is therefore relevant to compare the urinary concentrations in the case study with results from previous published codeine elimination studies. In our case study, 5 hours after the administration of 60 mg of codeine phosphate, the CEDIA buprenorphine assay produced a response >5 ng/mL cutoff. The corresponding urine codeine concentration, as measured by HPLC-MS/MS, was 2,550 ng/mL. This codeine concentration is somewhat lower than the concentrations from a previous study in which the pattern of codeine and metabolites in urine was examined in five patients after the intake of 30 mg of codeine.¹⁷ In that study, the urinary concentrations of codeine were ranging from 5,000 ng/mL to 20,000 ng/mL 12 hours after ingestion. In another study, four healthy volunteers were given 30 mg codeine phosphate. Codeine was detectable in urine from 1 hour to 24 hours, with a maximum excretion

rate after 2 hours. The highest concentrations were between 5,100 ng/mL and 13,300 ng/mL. Concentrations after 4 hours and 6 hours ranged from 500 ng/mL to 5,500 ng/mL.¹⁸ These data are in accordance with the results from our case study and strongly emphasize the clinical significance of cross-reactivity in the CEDIA buprenorphine assay even after intake of therapeutic doses of codeine.

Codeine is mainly metabolized by glucuronidation to C6G. The amount of C6G may vary by ethnicity.¹⁶ Genetic variability in the activity of CYP2D6 does primarily affect the demethylation of codeine to morphine and norcodeine and to a lesser extent the glucuronidation to C6G.¹⁹ It is possible that genetic factors that contribute to variations in metabolite concentrations are of importance for the generation of false-positive CEDIA buprenorphine results after intake of therapeutic codeine doses. Future research may contribute to elucidate this question.

Implications

If all urine samples positive for CEDIA buprenorphine were routinely analyzed also by a more specific method, such as HPLC-MS/MS, false-positive results would have been detected. Then, the recommended cutoff from the producer could be adequate, although the ROC analysis indicates that a higher cutoff would give a better accuracy in our population. Most buprenorphine-positive CEDIA samples, however, are not analyzed with HPLC-MS/MS in our laboratory, which is also common routine in several other laboratories in Norway. With the CEDIA buprenorphine assay, we have experienced that the clinicians may not question the assay results and may react also to false-positive samples with therapeutic means. These reactions include exclusion from drug abuse treatment institutions, more rigid treatment plans, and more frequent urine sample controls. In addition, false-positive samples could harm the doctor-patient relationship, giving both the doctor and the patient reason to lose confidence in each other. Therefore, we recommend increasing the cutoff for the CEDIA buprenorphine assay and propose 10 ng/mL for all practical reasons. Study results show that the higher cutoff does not completely remove the risk of false-positive samples. Clinicians should therefore be informed about the possible cross-reactivity and be encouraged to require a more specific analytical method in cases with unexpected positive CEDIA buprenorphine results. Still, a higher cutoff substantially diminishes the risk of false-positive samples caused both by codeine and its metabolites and other opioids, and thereby the risk of erroneous clinical interpretations.

Conclusion

Cross-reactivity in the CEDIA buprenorphine assay was seen even after intake of therapeutic doses of codeine phosphate. Metabolites of codeine and morphine may contribute to the cross-reactivity in urine samples from patients with drug abuse. The CEDIA buprenorphine cutoff concentration should be raised when the assay is used in a therapeutic setting without confirmatory analyses. Furthermore, clinicians should be well informed about the risk of false-positive results with the CEDIA buprenorphine assay.

Disclosure

The authors report no conflicts of interest in this work.

References

- Moody DE. Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine. *Expert Opin Drug Metab Toxicol*. 2013;9(6):675–697.
- EMCDDA. *European Drug Report 2014: Trends and Developments*. Available from: <http://www.emcdda.europa.eu/publications/edr/trends-developments/2014>. Accessed April 19, 2015.
- Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. *Curr Drug Abuse Rev*. 2011;4(1):28–41.
- Atluri S, Sudarshan G, Manchikanti L. Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011. *Pain Physician*. 2014;17(2):E119–E128.
- Böttcher M, Beck O. Evaluation of buprenorphine CEDIA assay versus GC-MS and ELISA using urine samples from patients in substitution treatment. *J Anal Toxicol*. 2005;29(8):769–776.
- Saleh A, Stephanson NN, Granelli I, Villén T, Beck O. Evaluation of a direct high-capacity target screening approach for urine drug testing using liquid chromatography-time-of-flight mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2012;909:6–13.
- George S. Position of immunological techniques in screening in clinical toxicology. *Clin Chem Lab Med*. 2004;42(11):1288–1309.
- Saitman A, Park HD, Fitzgerald RL. False-positive interferences of common urine drug screen immunoassays: a review. *J Anal Toxicol*. 2014;38(7):387–396.
- Thermo Fisher Scientific. *Drugs of Abuse Cross-Reactivity Guide, CEDIA Buprenorphine 5 ng/mL Cutoff*. Thermo Fisher Scientific, Clinical Diagnostics, Fremont; 2013. Available from: [http://www.thermoscientific.com/content/dam/tfs/SDG/CDD/CDD%20Documents/Product%20Manuals%20&%20Specifications/Diagnostic%20Testing%20Reagents/Drug%20of%20Abuse%20Testing%20\(DAT\)%20Calibrators%20Controls%20and%20Reagents/Drug%20of%20Abuse%20Reagents/CEDIA-Buprenorphine-5ng-mL-CRG-R14.pdf](http://www.thermoscientific.com/content/dam/tfs/SDG/CDD/CDD%20Documents/Product%20Manuals%20&%20Specifications/Diagnostic%20Testing%20Reagents/Drug%20of%20Abuse%20Testing%20(DAT)%20Calibrators%20Controls%20and%20Reagents/Drug%20of%20Abuse%20Reagents/CEDIA-Buprenorphine-5ng-mL-CRG-R14.pdf). Accessed April 19, 2015.
- Melanson SE, Snyder ML, Jarolim P, Flood JG. A new highly specific buprenorphine immunoassay for monitoring buprenorphine compliance and abuse. *J Anal Toxicol*. 2012;36(3):201–206.
- Pavlic M, Libiseller K, Grubwieser P, Rabl W. Cross-reactivity of the CEDIA buprenorphine assay with opiates: an Austrian phenomenon? *Int J Legal Med*. 2005;119(6):378–381.
- Hull MJ, Bierer MF, Griggs DA, Long WH, Nixon AL, Flood JG. Urinary buprenorphine concentrations in patients treated with suboxone as determined by liquid chromatography-mass spectrometry and CEDIA immunoassay. *J Anal Toxicol*. 2008;32(7):516–521.
- European Union. *Official Journal of the European Communities*; 2002; L 221/8. Available from: <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2002:221:0008:0036:EN:PDF>.
- Ferrara SD, Tedeschi L, Frison G, et al. Drugs-of-abuse testing in urine: statistical approach and experimental comparison of immunochemical and chromatographic techniques. *J Anal Toxicol*. 1994;18(5):278–291.
- Birch MA, Couchman L, Pietromartire S, et al. False-positive buprenorphine by CEDIA in patients prescribed amisulpride or sulpiride. *J Anal Toxicol*. 2013;37(4):233–236.
- Yue QY, Svensson JO, Alm C, Sjöqvist F, Säwe J. Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. *Br J Clin Pharmacol*. 1989;28(6):629–637.
- Posey BL, Kimble SN. High-performance liquid chromatographic study of codeine, norcodeine, and morphine as indicators of codeine ingestion. *J Anal Toxicol*. 1984;8(2):68–74.
- Delbeke FT, Debackere M. Urinary concentrations of codeine and morphine after the administration of different codeine preparations in relation to doping analysis. *J Pharm Biomed Anal*. 1991;9(10–12):959–964.
- Yue QY, Hasselström J, Svensson JO, Säwe J. Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. *Br J Clin Pharmacol*. 1991;31(6):635–642.

Supplementary material

Table S1 Analytical performance of HPLC-MS/MS for relevant analytes

Component	Calibration range ^a	Limit of detection ^a	Imprecision ^b (%)
6-Monoacetylmorphine	33–3,275	6.0	10.5
7-Aminoclonazepam	29–5,737	2.33	6.7
7-Aminoflunitrazepam	28–5,690	2.25	6.8
7-Aminonitrazepam	25–5,031	0.7	15.3
Alprazolam	31–6,178	0.9	5.1
Amphetamine	27–2,708	4.4	11.7
Benzoylcegonine	29–2,894	0.3	5.8
Cocaine	6–608	0.2	12.0
Codeine	30–2,997	6.9	16.3
Codeine-6-glucuronide	95–9,511	5.0	15.3
Desmethyldiazepam	54–10,832	3.5	5.1
Diazepam	3–570	1.9	10.4
EDDP	28–2,775	0.8	29.1
Ephedrine	33–3,320	5.5	13.6
Ethylmorphine	31–3,137	7.7	13.4
Hydrocodone	60–5,994	10.9	17.6
MDA	36–3,589	3.3	9.8
MDMA	39–3,873	1.0	10.7
Methadone	31–3,102	1.4	32.0
Methamphetamine	30–2,992	5.8	8.2
Morphine	29–2,855	9.0	17.1
Morphine-3-glucuronide	231–23,074	8.1	6.7
Morphine-6-glucuronide	139–13,851	15.0	8.5
N-desmethylzopiclone	38–7,513	2.6	7.5
Norcodeine	29–2,880	8.8	20.2
Oxazepam	57–11,470	4.4	7.5
Oxycodone	63–6,313	7.2	10.1
Temazepam	60–12,069	2.6	4.8
Zopiclone-N-oxide	41–8,122	1.5	11.3

Notes: ^aConcentrations are given in ng/mL; ^btotal analytical imprecision is calculated based on performance at lowest calibrator plus 25%.

Abbreviations: HPLC-MS/MS, high-performance liquid chromatography–tandem mass spectrometry; EDDP, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine; MDA, 3,4-methylenedioxy-amphetamine; MDMA, 3,4-methylenedioxy-methamphetamine.

Substance Abuse and Rehabilitation

Publish your work in this journal

Substance Abuse and Rehabilitation is an international, peer-reviewed, open access journal publishing original research, case reports, editorials, reviews and commentaries on all areas of addiction and substance abuse and options for treatment and rehabilitation. The manuscript management system is completely online and includes a very quick and fair

Submit your manuscript here: <http://www.dovepress.com/substance-abuse-and-rehabilitation-journal>

peer-review system. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress